Novo Nordisk A/S
NONOF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $20,006,000 | $26,503,000 | $29,034,000 | $28,230,000 |
| Dep. & Amort. | $3,237,000 | $4,833,000 | $3,830,000 | $5,198,000 |
| Deferred Tax | $0 | $7,302,000 | $7,999,000 | $7,327,000 |
| Stock-Based Comp. | $0 | $0 | $0 | $0 |
| Change in WC | -$4,960,000 | $4,755,000 | -$16,428,000 | -$981,000 |
| Other Non-Cash | $27,824,000 | -$2,608,000 | $156,000 | -$27,473,000 |
| Operating Cash Flow | $46,107,000 | $40,785,000 | $24,591,000 | $12,301,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$13,628,000 | -$14,661,000 | -$13,422,000 | -$16,101,000 |
| Net Acquisitions | $0 | $0 | $0 | -$81,495,000 |
| Inv. Purchases | $0 | -$582,000 | -$115,000 | -$353,000 |
| Inv. Sales/Matur. | $0 | $2,609,000 | $8,028,000 | $7,191,000 |
| Other Inv. Act. | -$1,797,000 | -$1,614,000 | -$1,164,000 | -$458,000 |
| Investing Cash Flow | -$15,425,000 | -$14,248,000 | -$6,673,000 | -$91,216,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$433,000 | -$19,622,000 | $15,331,000 | $44,326,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | $0 | $0 | -$1,388,000 | -$7,491,000 |
| Dividends Paid | -$16,663,000 | $174,000 | -$35,274,000 | $0 |
| Other Fin. Act. | $0 | -$26,782,000 | $26,782,000 | $0 |
| Financing Cash Flow | -$17,096,000 | -$46,230,000 | $5,451,000 | $36,835,000 |
| Forex Effect | $63,000 | -$810,000 | -$86,000 | $717,000 |
| Net Chg. in Cash | $13,649,000 | -$20,503,000 | $23,283,000 | -$41,363,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $18,435,000 | $38,938,000 | $15,655,000 | $57,018,000 |
| End Cash | $32,084,000 | $18,435,000 | $38,938,000 | $15,655,000 |
| Free Cash Flow | $32,479,000 | $24,510,000 | $10,005,000 | -$4,257,000 |